The original success of Sildenafil undeniably revolutionized the medication landscape, but investing in companies primarily reliant on generic versions presents a complex picture. Despite early earnings were substantial, the cessation of patents and the appearance of cheaper alternatives have diminished the customer base. Thus, a thorough evaluatio